Ying Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ying Huang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Jian Lin
Department of Pain, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
2 shared publications - Allison Sheen
Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts
1 shared publication - Benxiang Ning
Department of Pain, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
1 shared publication - Bin Liu
Central Laboratory, Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Affiliated Hospital of Hebei University, Baoding, Hebei, China
1 shared publication - Byong Ha Kang
Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA
1 shared publication - Chao Ma
Department of Pain, Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, China
1 shared publication
Latest Publications
- Open Access
- 1 November 2022
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 1 (5) , pgac244
Intratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
Confining cytokine exposure to the tumors would greatly enhance cancer immunotherapy safety and efficacy. Immunocytokines, cytokines fused to tumor-targeting antibodies, have been developed with this intention, but without significant clinical success to date. A critical limitation is uptake by receptor-expressing cells in the blood, that decreases the dose at the tumor and engenders toxicity. Small-format immunocytokines, constructed with antibody fragments, are hypothesized to improve tumor specificity due to rapid systemic clearance. However, effective design criteria for small-format immunocytokines need further examination. Here, we engineer small interleukin-2 (IL-2) immunocytokines fused to nanobodies with nanomolar to picomolar affinities for the tumor-specific EIIIB domain of fibronectin (also known as EDB). Upon intravenous delivery into immunocompetent mice, such immunocytokines led to similar tumor growth delay as size-matched untargeted IL-2. Intratumoral (i.t.) delivery imparted improved survival dependent on affinity to EIIIB. I.t. administration offers a promising avenue to deliver small-format immunocytokines, given effective affinity for the tumor microenvironment.
- 1 November 2022
- Published by Oxford University Press (OUP) in PNAS Nexus
- Vol. 1 (5) , pgac244
Open AccessIntratumoral nanobody–IL-2 fusions that bind the tumor extracellular matrix suppress solid tumor growth in mice
Confining cytokine exposure to the tumors would greatly enhance cancer immunotherapy safety and efficacy. Immunocytokines, cytokines fused to tumor-targeting antibodies, have been developed with this intention, but without significant clinical success to date. A critical limitation is uptake by receptor-expressing cells in the blood, that decreases the dose at the tumor and engenders toxicity. Small-format immunocytokines, constructed with antibody fragments, are hypothesized to improve tumor specificity due to rapid systemic clearance. However, effective design criteria for small-format immunocytokines need further examination. Here, we engineer small interleukin-2 (IL-2) immunocytokines fused to nanobodies with nanomolar to picomolar affinities for the tumor-specific EIIIB domain of fibronectin (also known as EDB). Upon intravenous delivery into immunocompetent mice, such immunocytokines led to similar tumor growth delay as size-matched untargeted IL-2. Intratumoral (i.t.) delivery imparted improved survival dependent on affinity to EIIIB. I.t. administration offers a promising avenue to deliver small-format immunocytokines, given effective affinity for the tumor microenvironment.
- Open Access
- 1 April 2021
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 34 (2) , 210-216
Intravenous patient-controlled analgesia hydromorphone combined with pregabalin for the treatment of postherpetic neuralgia: a multicenter, randomized controlled study
Ying Huang, Chenjie Xu, Tao Zeng, Zhongming Li, Yanzhi Xia, Gaojian Tao, Tong Zhu, Lijuan Lu, Jing Li, Taiyuan Huang, Hongbo Huai, Benxiang Ning, Chao Ma, Xinxing Wang, Yuhua Chang, Peng Mao, and Jian Lin. Korean J Pain 2021;34:210-6. https://doi.org/10.3344/kjp.2021.34.2.210
- 1 April 2021
- Published by Korean Pain Society in The Korean Journal of Pain
- Vol. 34 (2) , 210-216
Open AccessIntravenous patient-controlled analgesia hydromorphone combined with pregabalin for the treatment of postherpetic neuralgia: a multicenter, randomized controlled study
Ying Huang, Chenjie Xu, Tao Zeng, Zhongming Li, Yanzhi Xia, Gaojian Tao, Tong Zhu, Lijuan Lu, Jing Li, Taiyuan Huang, Hongbo Huai, Benxiang Ning, Chao Ma, Xinxing Wang, Yuhua Chang, Peng Mao, and Jian Lin. Korean J Pain 2021;34:210-6. https://doi.org/10.3344/kjp.2021.34.2.210
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi214
KRAS mutation and protein levels in gastric cancer patients and response to MEK inhibitors
Background: Recent studies have suggested that KRAS plays an important role in gastric cancer. The aim of this study was to assess the prognostic effect of KRAS mutation and expression levels in gastric cancer patients and to explore its potential role in targeted therapy.
- 11 October 2016
- Published by Elsevier in Annals of Oncology
- Vol. 27 (suppl_6) , vi214
KRAS mutation and protein levels in gastric cancer patients and response to MEK inhibitors
Background: Recent studies have suggested that KRAS plays an important role in gastric cancer. The aim of this study was to assess the prognostic effect of KRAS mutation and expression levels in gastric cancer patients and to explore its potential role in targeted therapy.
- Open Access
- 1 January 2015
- Published by Wiley in Mediators of Inflammation
- Vol. 2015 (1) , 439014
Efficacy and Safety of Ropivacaine Addition to Intrathecal Morphine for Pain Management in Intractable Cancer
Objective. Although intrathecal drug infusion has been commonly adopted for terminal cancer pain relief, its adverse effects have made many clinicians reluctant to employ it for intractable cancer pain. The objective of this study is to compare the efficacy and security of an intrathecal continuous infusion of morphine and ropivacaine versus intrathecal morphine alone for cancer pain.Methods. Thirty‐six cancer patients received either a continuous morphine (n= 19) or morphine and ropivacaine (n= 17) infusion using an intrathecal catheter through a subcutaneous port. Numerical Rating Scale (NRS) scores and the Barthel Index were analyzed. Adverse effects and complications on postoperative days 1, 3, 7, and 15 were also analyzed.Results. All patients experienced pain relief. Compared to those who received morphine alone, patients receiving morphine and ropivacaine had significantly lower postoperative morphine requirements and higher Barthel Index scores on the 15th postsurgical day (P< 0.05). Patients receiving morphine and ropivacaine had lower NRS scores than patients receiving morphine alone on postoperative days 1, 3, 7, and 15 (P< 0.05). Negative postsurgical effects were similar in both groups.Conclusions. Morphine and ropivacaine administration through intrathecal access ports is efficacious and safe and significantly improves quality of life.
- 1 January 2015
- Published by Wiley in Mediators of Inflammation
- Vol. 2015 (1) , 439014
Open AccessEfficacy and Safety of Ropivacaine Addition to Intrathecal Morphine for Pain Management in Intractable Cancer
Objective. Although intrathecal drug infusion has been commonly adopted for terminal cancer pain relief, its adverse effects have made many clinicians reluctant to employ it for intractable cancer pain. The objective of this study is to compare the efficacy and security of an intrathecal continuous infusion of morphine and ropivacaine versus intrathecal morphine alone for cancer pain.Methods. Thirty‐six cancer patients received either a continuous morphine (n= 19) or morphine and ropivacaine (n= 17) infusion using an intrathecal catheter through a subcutaneous port. Numerical Rating Scale (NRS) scores and the Barthel Index were analyzed. Adverse effects and complications on postoperative days 1, 3, 7, and 15 were also analyzed.Results. All patients experienced pain relief. Compared to those who received morphine alone, patients receiving morphine and ropivacaine had significantly lower postoperative morphine requirements and higher Barthel Index scores on the 15th postsurgical day (P< 0.05). Patients receiving morphine and ropivacaine had lower NRS scores than patients receiving morphine alone on postoperative days 1, 3, 7, and 15 (P< 0.05). Negative postsurgical effects were similar in both groups.Conclusions. Morphine and ropivacaine administration through intrathecal access ports is efficacious and safe and significantly improves quality of life.